ECCO 2025

Personalized dosing of infliximab in moderate to severe UC

The importance of endoscopic surveillance – current techniques and a bright future?

No treatment choices anymore? Efficacy and safety of autologous hematopoietic stem cell transplantation in CD

Eating is part of life – and of special therapeutic importance in IBD patients!

Surgical approaches in IBD – all questions solved?

New UC-kids on the block: a IL7 receptor antagonist & an anti-TNF/anti-IL-23 bispecific AB

Comparative efficacy between biologics in UC – the need for H2H-trials

The perfect dosing of our drugs – data on ustekinumab and vedolizumab in CD

Anti-TL1a – a new treatment option in IBD and unsolved questions

What is the best treatment goal for moderate to severe UC?

Urgency – what is hen and what is egg?

Comparative efficacy and safety – do we need to reassess JAKis?

Update on fistulizing disease

Old vs. new – ustekinumab vs. modern IL23

Combination therapies – on the way to the holy grail?

Subcutaneous therapy with guselkumab for Crohn's disease and ulcerative colitis

Subcutaneous induction with guselkumab in CD is effective!

Autologous HSCT – still an option for refractory CD?

Kono-S anastomosis is not superior to side-to-side anastomosis to prevent endoscopic recurrence in CD

The need for early treatment in Crohn’s disease – a Chinese perspective

Early CD treatment with vedolizumab

Dose escalation of vedolizumab in CD is not effective

Rola wczesnej terapii choroby Leśniowskiego-Crohna – dane chińskie

HSCT autologue – toujours une option pour la maladie de Crohn réfractaire?

Subkutane Therapie mit Guselkumab bei Morbus Crohn und Colitis ulcerosa

La anastomosis Kono-S no es superior a la anastomosis side-to-side para prevenir la recurrencia endoscópica en la enfermedad de Crohn

Subcutaneous therapy with guselkumab for Crohn's disease and ulcerative colitis

Obefazimod maintenance treatment: a new approach

How to treat UC patients after failure of a s.c. anti-TNF?

Appendectomy – a good option for UC

Long-term efficacy and safety of a lower obefazimod maintenance dose

First combination of upadacitinib and vedolizumab in ulcerative colitis

Personalized dosing in acute UC

Comment traiter la RCH après l'échec d'un anti-TNF s.c.?

Obefazimod in der Erhaltung: Neuer Ansatz

Long-term efficacy and safety of a lower obefazimod maintenance dose

Appendektomie – eine gute Option bei Colitis Ulcerosa

Subkutane Therapie mit Guselkumab bei Morbus Crohn und Colitis ulcerosa

Erste Kombination von Upadacitinib und Vedolizumab bei Colitis ulcerosa

s.c.? i.v.? Just swallow it! News from the oral bispecific anti-TNFα and anti-IL-23p19 antibody SOR102

SOR102 – a novel oral bispecific antibody in patients with active UC

New mode of action for treating UC

A new class of drugs: anti-TL1A antibodies

Lusvertikimab – a first-in-class IL7 receptor antagonist for patients with UC

New treatments – fast forward to the future

s.c.? i.v.? Einfach schlucken! Neues vom oralen bispezifischen anti-TNFα und anti-IL-23p19 Antikörper SOR102

טיפולים חדשים- fast forward לעתיד

Eine neue Substanzklassen: Anti-TL1A Antikörper

SOR102 – un nuovo anticorpo bispecifico orale in pazienti con UC attiva

Nouveau mode d'action pour le traitement de la RCH

Lusvertikimab – un antagonista del recettore IL7 di prima classe per i pazienti con UC

Association between histologic response and histo-endoscopic / clinical outcomes after Mirikizumab induction in CD

Mirikizumab demonstrates rapid improvements in bowel urgency in moderately-to-severely active UC

Minimal Residual Disease: a new treatment goal in IBD?

Defining radiological healing in perianal fistulising Crohn’s Disease: a global modified Delphi consensus

What is the best treatment goal for moderate to severe UC?

Comprehensive approach necessary to treat our patients the best way possible!

Was ist der beste Therapieendpunkt bei moderater bis schwerer UC?

Mirikizumab demonstrates rapid improvements in bowel urgency in moderately-to-severely active UC

Minimal Residual Disease: ein neuer Endpunkt bei CED?

Definiendo la curación radiológica en enfermedad de Crohn perianal fistulizante: resultados de un consenso Delphi modificado global

גישה כוללנית הכרחית לטיפול בחולים בדרך המיטבית

Tasty&Healthy – the next step towards anti-inflammatory diets!

A low emulsifier diet is a treatment for moderate to severe CD

Fibre consumption and the risk of developing CD

Tasty&Healthy diet is better tolerated than exclusive enteral nutrition

Spożycie błonnika a ryzyko zachorowania na chorobę Leśniowskiego-Crohna

Tasty&Healthy – der nächste Schritt zu einer entzündungshemmenden Ernährung!

Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in UC patients

Effectiveness & safety of advanced combination therapy in pts. with refractory IBD or concomittant IMID

Etrasimod improves clinical, endoscopic and histologic outcomes in UC

PODIUM: effectiveness & safety of 2nd line vedolizumab or ustekinumab or JAKies after anti-TNF therapy

ASTRO study established the efficacy of guselkumab subcutaneous induction (week 12) in UC patients

PODIUM: efficacia e sicurezza di Vedolizumab o Ustekinumak o JAKi di seconda linea dopo terapia anti-TNF

El estudio ASTRO demuestra la eficacia de Guselkumab en inducción por vía subcutánea (semana 12) en pacientes con colitis ulcerosa

Efficacia e sicurezza di una terapia combinata avanzata nelle mallatie inflammatorie croniche intestinali refrattarie

Eficacia comparativa de infliximab vs. vedolizumab tras fallo a un primer anti-TNF en pacientes con colitis ulcerosa

Optimizing biologics in CD – is it relevant for all?

Infliximab induction fails to reach target drug level in perinal fistulizing CD

Second line treatment for perianal Crohn's disease

Dose escalation of primary non-responders is not effective!

Effectiveness & safety of advanced combination therapy in pts. with refractory IBD or concomittant IMID

Mancato aumento dei livelli terapeutici di IFX nella malattia di Crohn complicata da malattia perianale

Efficacia e sicurezza di una terapia combinata avanzata nelle mallatie inflammatorie croniche intestinali refrattarie

Zweitlinie bei Crohn-Fisteln

אופטימיזציה של תכשירים ביולוגים במחלת קרוהן-האם מתאים לכולם?

Psychological factors and the risk of IBD flare

Risk of IMID associated with anti-TNF and ustekinumab in CD

Czynniki psychologicne a ryzyko zaostrzenia IBD

Rischio di IMID associato al trattamento con anti-TNF e con ustekinumab

How to detect preneoplastic lesions by coloscopy

αvβ6 – new biomarker in prediciting, staging and monitoring CD

Comment détecter les lésions prénéoplasiques par coloscopie

αvβ6 – ein neuer Biomarker zur Prädiktion, Staging und Monitoring von Morbus Crohn

A new classification of IBD – 20 years later!

Une nouvelle classification des MICI – 20 ans après!

Identification of CD and UC specific clonotypes

HLA typing – tailoring treatment a step forward?

סיווג HLA-התקדמות בטיפול מותאם אישית?

Identificazione di clonotipi specifici nella malattia di Crohn e nella colite ulcerosa